-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2023-504713-76-00
5
2024-12-03
Dermatitis atopic
-
2023-507351-29-00
5
2024-12-03
Alzheimer's Disease Psychosis
-
2023-507660-39-00
5
2024-12-03
Myotonic dystrophy type 1 (DM1)
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2023-508400-38-00
4
2024-11-29
meningioma
-
2023-508208-40-00
10
2024-11-21
All adult patients with successful transfemoral trans-aortic valve imp
-
2024-511313-38-00
4
2024-11-17
Soft Tissue Sarcoma
-
2023-508704-37-00
5
2024-11-08
Stroke
-
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-516101-23-00
5
2024-10-28
Sarcoidosis
-
2023-504755-26-00
4
2024-10-21
Bronchiectasis
-
2024-514875-16-00
4
2024-10-21
First-line treatment of PD-L1-positive recurrent or metastatic head an
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-508539-30-00
4
2024-10-10
Refractory Focal Onset Epilepsy
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-509073-23-00
4
2024-10-01
Stage III/IV non-small-cell lung cancer (NSCLC) harboring an ROS1 gene
-
2023-504986-22-00
5
2024-09-30
surgical antibiotic prophylaxis
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)